Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -63.99
- Piotroski Score 1.00
- Grade Neutral
- Symbol (NEXI)
- Company NexImmune, Inc.
- Price $0.30
- Changes Percentage (36.24%)
- Change $0.08
- Day Low $0.30
- Day High $0.30
- Year High $28.70
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/21/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $5.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$24.11
- Trailing P/E Ratio -0.12
- Forward P/E Ratio -0.12
- P/E Growth -0.12
- Net Income $-32,344,392
Income Statement
Quarterly
Annual
Latest News of NEXI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Trump win fuels discussion of Israel annexing the West Bank. Here's what that means.
Israel's far-right finance minister proposed annexing the West Bank by 2025, amid ongoing conflict with Palestinians. This move challenges the traditional two-state solution and raises concerns over s...
By CBS News | 3 days ago -
Israel's true objective in northern Gaza? Removing Palestinians - and annexing the territory | Ben Reiff
Israeli settlers aim to return to Gaza, as IDF officer admits to ethnic cleansing in northern Gaza. Civilians are being forced out of homes, facing starvation. Israeli officials hint at annexation pla...
By The Guardian | 1 week ago -
Giants have gotten used to losing with hope nearly nonexistent
The New York Giants are facing a familiar struggle with a 2-5 record, a situation their longest-tenured players are accustomed to. Despite the challenges, players like Dexter Lawrence maintain hope an...
By New York Post | 3 weeks ago
